William L. Macias - 11 Jan 2023 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Signature
/s/ Eva Renee Barnett, attorney-in-fact for William L. Macias
Issuer symbol
IMVT
Transactions as of
11 Jan 2023
Net transactions value
-$746,317
Form type
4
Filing time
13 Jan 2023, 07:13:29 UTC
Previous filing
25 Oct 2022
Next filing
03 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Sale $1,813 -120 -0.04% $15.11 307,981 11 Jan 2023 Direct F1, F2
transaction IMVT Common Stock Sale $744,504 -44,448 -14% $16.75 263,533 11 Jan 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 5, 2021, the holder was granted 112,108 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 9, 2021. These RSUs vested in their entirety on January 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of these RSUs and do not represent a discretionary sale by the holder.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.06 - $15.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.30 - $16.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.